ADVERTISEMENT

Clinical Summary

Advanced ovarian cancer: extended bevacizumab has no benefit

Deepa Koli   |   15 November 2022

Takeaway

  • Extending bevacizumab treatment duration to 30 months does not improve PFS, OS, and objective response rate vs 15-month standard regimen in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or peritoneal cancer undergoing surgery followed by chemotherapy plus bevacizumab.

Why this matters

  • Findings show that extending bevacizumab duration has...

          

November Challenge

Ends in 11h
left
right

Topic Challenges

left
right